Ãֽſ¬±¸°á°ú : ±Þ¼º°ñ¼ö¼º¹éÇ÷º´(Acute myeloid leukemia, AML)ÀÇ
öºÐ ų·¹ÀÌÆ®(Iron chelation therapy) Ä¡·áÈ¿°ú: ÃÇ°èÀû °íÂû°ú ¸ÞŸºÐ¼®
¿¬±¸¸ñÀû :
öºÐ ų·¹ÀÌÆ® ¿ä¹ý (Iron chelation therapy, ICT)ÀÌ ÀúÀ§Çè ȤÀº ÁßÀ§ÇèÀÇ °ñ¼öÀÌÇü¼ºÁõÈıº(low- or intermediate-risk myelodysplastic syndromes, MDS)À» °¡Áø ȯÀÚÀÇ Àü¹ÝÀûÀÎ »ýÁ¸·ü(Overall survival, OS)°ú ÁøÇà¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Á¶»çÇϱâ À§ÇÔ
¿¬±¸¼³°è :
ü°èÀû °íÂû ¹× ¸ÞŸºÐ¼® ¿¬±¸
¿¬±¸¹æ¹ý :
°Ë»ö DB :
PubMed, EMBASE, Cochrane databases,
World Health Organization Clinical Trial Registry
¿¬±¸ ÀÚ·á :
9°³ÀÇ °üÂû¿¬±¸ : 4°³ÀÇ ÀüÇâÀû ¿¬±¸¿Í 5°³ÀÇ ÈÄÇâÀû ¿¬±¸
(9 observational studies : 4 prospective & 5 retrospective)
°á°ú :
ICT »ç¿ë±ºÀº ±×·¸Áö ¾ÊÀº ±×·ì¿¡ ºñÇÏ¿© Àü¹ÝÀûÀ¸·Î »ç¸Á·üÀÌ ³·¾Ò´Ù (aHR 0.42; 95% confidence interval (CI) 0.28-0.62; P < 0.01). ±×·¯³ª ¿¬±¸ÀÚ·áµéÀ» ºñ±³ÇØ º¼¶§ »ó´çÇÑ ÀÌÁú¼ºÀÌ ÀÖ¾ú´Ù.±Þ¼º°ñ¼ö¼º¹éÇ÷º´(acute myeloid leukemia, AML)ÀÇ ÁøÇàÀ» º¸°íÇÑ ¿¬±¸¿¡¼´Â ICT ¿ä¹ýÀº ÁøÇà À§Çè °¨¼Ò¿Í °ü·ÃÀÌ ¾ø¾ú´Ù((±³Â÷ºñ 0.68; 95 % CI 0.31-1.43; P <0.030)
Ãâó : Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes (2018). Ann Hematol. 2018 Nov 9.
Doi: 10.1007/s00277-018-3539-7.